Ibrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
94.74
Gini
0.723
CATDS
0.018
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ibrutinib. Strongest target: ERBB4_HER4 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 100.0% | 0.0% |
| 2 | TXK | 99.9% | 0.1% |
| 3 | BLK | 99.7% | 0.3% |
| 4 | EGFR | 99.3% | 0.7% |
| 5 | CSK | 99.3% | 0.7% |
| 6 | FGR | 99.1% | 0.9% |
| 7 | BMX_ETK | 98.9% | 1.1% |
| 8 | ERBB2_HER2 | 98.8% | 1.2% |
| 9 | BTK | 98.8% | 1.3% |
| 10 | TEC | 98.7% | 1.3% |
| 11 | JAK3 | 98.6% | 1.4% |
| 12 | LCK | 98.0% | 2.0% |
| 13 | YES_YES1 | 96.5% | 3.5% |
| 14 | BRK | 96.5% | 3.5% |
| 15 | LYN | 95.7% | 4.3% |
| 16 | HCK | 95.1% | 4.9% |
| 17 | MKK7 | 94.8% | 5.2% |
| 18 | CK2A2 | 94.7% | 5.3% |
| 19 | ITK | 94.5% | 5.5% |
| 20 | RIPK3 | 92.9% | 7.1% |
Selectivity landscape
Where Ibrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ibrutinib.
Atlas insights for Ibrutinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2292.99 | |
| ALLOGRAFT_REJECTION | 9523.08 | |
| ANDROGEN_RESPONSE | 1843.22 | |
| ANGIOGENESIS | 1761.76 | |
| APICAL_JUNCTION | 9481.44 | |
| APICAL_SURFACE | 986.75 | |
| APOPTOSIS | 6236.80 | |
| BILE_ACID_METABOLISM | 1025.39 | |
| CHOLESTEROL_HOMEOSTASIS | 1495.04 | |
| COAGULATION | 1092.75 | |
| COMPLEMENT | 5430.17 | |
| DNA_REPAIR | 1376.78 | |
| E2F_TARGETS | 3160.09 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1865.45 | |
| ESTROGEN_RESPONSE_EARLY | 2236.22 | |
| ESTROGEN_RESPONSE_LATE | 2202.67 | |
| FATTY_ACID_METABOLISM | 961.94 | |
| G2M_CHECKPOINT | 3204.62 | |
| GLYCOLYSIS | 2255.97 | |
| HEDGEHOG_SIGNALING | 849.71 | |
| HEME_METABOLISM | 1619.16 | |
| HYPOXIA | 3385.11 | |
| IL2_STAT5_SIGNALING | 2858.23 | |
| IL6_JAK_STAT3_SIGNALING | 4388.83 | |
| INFLAMMATORY_RESPONSE | 4965.88 | |
| INTERFERON_ALPHA_RESPONSE | 943.66 | |
| INTERFERON_GAMMA_RESPONSE | 5592.82 | |
| KRAS_SIGNALING_DN | 856.62 | |
| KRAS_SIGNALING_UP | 3482.66 | |
| MITOTIC_SPINDLE | 5529.85 | |
| MTORC1_SIGNALING | 3582.15 | |
| MYC_TARGETS_V1 | 2398.24 | |
| MYC_TARGETS_V2 | 457.22 | |
| MYOGENESIS | 2582.12 | |
| NOTCH_SIGNALING | 183.54 | |
| OXIDATIVE_PHOSPHORYLATION | 1587.23 | |
| P53_PATHWAY | 2898.79 | |
| PANCREAS_BETA_CELLS | 108.25 | |
| PEROXISOME | 871.15 | |
| PI3K_AKT_MTOR_SIGNALING | 8373.25 | |
| PROTEIN_SECRETION | 2002.29 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 460.94 | |
| SPERMATOGENESIS | 1267.47 | |
| TGF_BETA_SIGNALING | 1384.57 | |
| TNFA_SIGNALING_VIA_NFKB | 3490.77 | |
| UNFOLDED_PROTEIN_RESPONSE | 981.16 | |
| UV_RESPONSE_DN | 4093.67 | |
| UV_RESPONSE_UP | 3077.40 | |
| WNT_BETA_CATENIN_SIGNALING | 1684.74 | |
| XENOBIOTIC_METABOLISM | 2119.91 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.823 |
| EPT0291 | EPN | 0.812 |
| SRR10899984 | — | 0.809 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.807 |
| aMVAC.P_005_TURBT_S223 | — | 0.802 |
Annotations
Sign in to read and post annotations.
Loading…